Andrews, C., Abraham, A., Grogan, C. M., et al. (2015). Despite resources from the ACA, Most states do little to help addiction treatment programs implement health care reform. Health Affairs (Millwood), 5, 828–835.CrossRefGoogle Scholar

Barh, D., García-Solano, M. E., Tiwari, S., et al. (2017). BARHL1 is downregulated in Alzheimer’s disease and may regulate cognitive functions through ESR1 and multiple pathways. Genes (Basel), 10, 245.Google Scholar

Baron, D., Blum, K., Chen, A., Gold, M. & Badgaiyan, R. D. (2018). Conceptualizing addiction from an osteopathic perspective:Dopamine homeostasis. Journal of the American Osteopathic Association, 118, 115–118.Google Scholar

Barratt, D. T., Coller, J. K. & Somogyi, A. A. (2006). Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. American Journal of Medical Genetics Part B Neuropsychiatric Genetics, 141, 323–331.Google Scholar

Berridge, K. C. & Robinson, T. E. (2016). Liking, wanting, and the incentive-sensitization theory of addiction. American Psychologist Journal, 71, 670–679.CrossRefGoogle ScholarPubMed

Bershad, A. K., Miller, M. A., Norman, G. J. & de Wit, H. (2018). Effects of opioid- and non-opioid analgesics on responses to psychosocial stress in humans. Hormones and Behavior, 102, 41–47.Google Scholar

Blum, K. (2017). Reward Deficiency Syndrome. The Sage Encyclopedia of Abnormal Clinical Psychology, Wenzel, A. (Ed.). Pennsylvania: Sage Publications.Google Scholar

Blum, K. & Baron, D. (2019). Opioid substitution therapy: Achieving harm reduction while searching for a prophylactic solution. Current Pharmaceutical Biotechnology, 20, 180–182.CrossRefGoogle ScholarPubMed

Blum, K., Badgaiyan, R. D., Braverman, E. R., et al. (2016a). Hypothesizing that, a pro-dopamine regulator (KB220Z) should optimize, but not hyper-activate the activity of Trace Amine-Associated Receptor 1 (TAAR-1) and induce anti-craving of psychostimulants in the long-term. Journal of Reward Deficiency Syndrome Addiction Science, 2, 14–21.Google Scholar

Blum, K., Chen, A. L., Chen, T. J., et al. (2008a). Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long-term treatment of reward deficiency syndrome (RDS): A commentary. Theoretical Biology Medical Modelling, 12(5), 24.Google Scholar

Blum, K., Chen, T. J., Meshkin, B., et al. (2007a) Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: Hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). Medical Hypotheses, 68, 844–852.CrossRefGoogle ScholarPubMed

Blum, K., Chen, A. L., Oscar-Berman, M., et al. (2011). Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: Selecting appropriate phenotypes for reward dependence behaviors. International Journal of Environmental Research and Public Health, 8, 4425–4459.CrossRefGoogle ScholarPubMed

Blum, K., Chen, A. L. C., Thanos, P. K., et al. (2018a). Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence. Frontiers in Bioscience (Elite Edition), 10, 175–196.Google Scholar

Blum, K., Chen, T. J., Meshkin, B., et al. (2007b). Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: Hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). Medical Hypotheses, 68, 844–852.Google Scholar

Blum, K., Chen, T. J., Morse, S., et al. (2010). Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D2 agonist therapy: Part 2. Postgraduate Medical Journal, 122, 214–226.Google Scholar

Blum, K., Chen, T. J. H., Chen, A. L. C., et al. (2008b). Dopamine D2 receptor Taq A1 allele predicts treatment compliance of LG839 in a subset analysis of pilot study in the Netherlands. Gene Therapy & Molecular Biology, 12, 129–140.Google Scholar

Blum, K., Febo, M. & Badgaiyan, R. D. (2016b). Fifty years in the development of a glutaminergic-dopaminergic optimization complex (KB220) to balance brain reward circuitry in Reward Deficiency Syndrome: A pictorial. Austin Addiction Sciences, 1, 1006.Google ScholarPubMed

Blum, K., Febo, M., Badgaiyan, R. D., et al. (2017a). Common neurogenetic diagnosis and meso-limbic manipulation of hypodopaminergic function in Reward Deficiency Syndrome (RDS): Changing the recovery landscape. Current Neuropharmacology, 15, 184–194.Google Scholar

Blum, K., Febo, M., Fried, L., et al. (2017b). Hypothesizing that neuropharmacological and neuroimaging studies of glutaminergic-dopaminergic optimization complex (KB220Z) are associated with “dopamine homeostasis” in Reward Deficiency Syndrome (RDS). Substance Use and Misuse, 52, 535–547.CrossRefGoogle ScholarPubMed

Blum, K., Febo, M., McLaughlin, T., et al. (2014a). Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric. Journal of Behavioral Addictions, 3, 149–156.Google Scholar

Blum, K., Febo, M., Thanos, P. K., et al. (2015a). Clinically combating Reward Deficiency Syndrome (RDS) with dopamine agonist therapy as a paradigm shift: Dopamine for dinner? Molecular Neurobiology, 52, 1862–1869.CrossRefGoogle ScholarPubMed

Blum, K., Gardner, E., Oscar-Berman, M. & Gold, M. (2012). “Liking” and “wanting” linked to Reward Deficiency Syndrome (RDS): Hypothesizing differential responsivity in brain reward circuitry. Current Pharmaceutical Design, 18, 113–118.Google Scholar

Blum, K., Han, D., Hauser, M., et al. (2013a). Neurogenetic impairments of brain reward circuitry links to Reward Deficiency Syndrome (RDS) as evidenced by Genetic Addiction Risk Score (GARS): A case study. The Institute of Integrative Omics and Applied Biotechnology Journal, 4, 4–9.Google Scholar

Blum, K., Han, D., Modestino, E. J., et al. (2018b). A systematic, intensive statistical investigation of data from the Comprehensive Analysis of Reported Drugs (CARD) for compliance and illicit opioid abstinence in substance addiction treatment with buprenorphine/naloxone. Substance Use and Misuse, 53, 220–229.Google Scholar

Blum, K., Han, D., Femino, J., et al. (2014b). Systematic evaluation of “compliance” to prescribed treatment medications and “abstinence” from psychoactive drug abuse in chemical dependence programs: Data from the comprehensive analysis of reported drugs. PLoS ONE, 9, e104275.Google Scholar

Blum, K., Jacobs, W., Modestino, E. J., et al. (2018c). Insurance companies fighting the peer review empire without any validity: The case for addiction and pain modalities in the face of an American drug epidemic. SEJ Surgery and Pain, 1, 1–11.Google Scholar

Blum, K., Liu, Y., Wang, W., et al. (2015b). rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts. Postgraduate Medical Journal, 127, 232–241.Google Scholar

Blum, K., Lott, L. Siwicki, D., et al. (2018d). Genetic Addiction Risk Score (GARS) as a predictor of substance use disorder: Identifying predisposition not diagnosis. Current Trends in Medical Diagnostic Methods, 1, 1–3.Google Scholar

Blum, K., Madigan, M. A., Fried, L., et al. (2017c). Coupling Genetic Addiction Risk Score (GARS) and pro dopamine regulation (KB220) to combat substance use disorder (SUD). Global Journal of Addiction and Rehabilitation Medicine, 1.Google Scholar

Blum, K., Modestino, E. J., Gondre-Lewis, M., et al. (2018e). The benefits of Genetic Addiction Risk Score (GARS™) testing in Substance Use Disorder (SUD). International Journal of Genomics and Data Mining, 1, 115.Google Scholar

Blum, K., Modestino, E. J., Gondré-Lewis, M. C., et al. (2017d). Global opioid epidemic: Doomed to fail without genetically based precision addiction medicine (PAMTM): Lessons learned from America. Journal of Laboratory and Precision Medicine (Bangalore), 2, 17–22.Google Scholar

Blum, K., Modestino, J. E., Gondre Lewis, C. M., et al. (2018f). Pro-dopamine regulator (KB220) a fifty year sojourn to combat Reward Deficiency Syndrome (RDS): Evidence based bibliography (annotated). CPQ Journal of Neurology and Psychology, 1.Google Scholar

Blum, K., Modestino, E. J., Lott, L., et al. (2018g). Introducing “Precision Addiction Management (PAM^®)” as an adjunctive genetic guided therapy for abusable drugs in America. Open Access Journal of Psychology and Behavioral Science, 1, 1–4.Google Scholar

Blum, K., Modestino, E. J., Neary, J., et al. (2018h). Promoting Precision Addiction Management (PAM) to combat the global opioid crisis. Biomedical Journal of Scientific and Technical Research, 2, 1–4.CrossRefGoogle ScholarPubMed

Blum, K., Noble, E. P., Sheridan, P. J., et al. (1990). Allelic association of human dopamine D2 receptor gene in alcoholism. The Journal of American Medical Association, 263(15), 2055–2060.Google Scholar

Blum, K., Oscar-Berman, M., Demetrovics, Z., Barh, D. & Gold, M. S. (2014c). Genetic Addiction Risk Score (GARS): Molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS). Molecular Neurobiology, 50, 765–796.CrossRefGoogle ScholarPubMed

Blum, K., Oscar-Berman, M., Femino, J., et al. (2013b). Withdrawal from buprenorphine/naloxone and maintenance with a natural dopaminergic agonist: A cautionary note. Journal of Addiction Research and Therapy, 4.Google Scholar

Blum, K., Thompson, B., Demotrovics, Z., et al. (2015c). The molecular neurobiology of twelve steps program & fellowship: Connecting the dots for recovery. Journal of Reward Deficiency Syndrome, 1, 46–64.Google Scholar

Blum, K., Wood, R. C., Braverman, E. P., Chen, T. J. H. & Sheridan, P. J. (1995). D2 dopamine receptor gene as a predictor of compulsive disease: Bayes’ theorem. Functional Neurology, 10, 37–44.Google Scholar

Bousman, C., Maruf, A. A. & Müller, D. J. (2019). Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel. Current Opinion in Psychiatry, 32, 7–15.CrossRefGoogle ScholarPubMed

Casey, B. J., Craddock, N., Cuthbert, B. N., Hyman, S. E., Lee, F. S. & Ressler, K. J. (2013). DSM-5 and RDoC: progress in psychiatry research? Nature reviews. Neuroscience, 14, 810–814.Google Scholar

Chen, A. L., Blum, K., Chen, T. J., et al. (2012). Correlation of the Taq1 dopamine D2 receptor gene and percent body fat in obese and screened control subjects: a preliminary report. Food and Function, 3, 40–48.CrossRefGoogle ScholarPubMed

Chen, A. L., Chen, T. J., Waite, R. L., et al. (2009). Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions. Medical Hypotheses, 72, 14–22.CrossRefGoogle ScholarPubMed

Chen, D., Liu, F., Shang, Q., et al. (2011). Association between polymorphisms of DRD2 and DRD4 and opioid dependence: evidence from the current studies. American Journal of Medical Genetics, 156, 661–670.Google Scholar

Chen, T. J., Blum, K., Mathews, D., et al. (2005). Are dopaminergic genes involved in a predisposition to pathological aggression? Hypothesizing the importance of “super normal controls” in psychiatricgenetic research of complex behavioral disorders. Medical Hypotheses, 65, 703–707.Google Scholar

Comings, D. E., MacMurray, J., Johnson, P., Dietz, G. & Muhleman, D. (1995). Dopamine D2 receptor gene (DRD2) haplotypes and the defense style questionnaire in substance abuse, Tourette syndrome, and controls. Biological Psychiatry, 37, 798–805.Google Scholar

Corrigan, P. W., Schomerus, G., Shuman, V., et al. (2017). Developing a research agenda for reducing the stigma of addictions, part II: lessons from the mental health stigma literature. American Journal on Addictions, 1, 67–74.Google Scholar

Dahlgren, A., Wargelius, H. L., Berglund, K. J., et al. (2011). Do alcohol-dependent individuals with DRD2 A1 allele have an increased risk of relapse? Alcohol and Alcoholism, 46, 509–513.Google Scholar

Dunn, K E. & Strain, E. C. (2013). Pretreatment alcohol drinking goals are associated with treatment outcomes. Alcoholism: Clinical and Experimental Research, 37, 1745–1752.Google Scholar

Elston, S. F., Blum, K., DeLallo, L. & Briggs, A. H. (1982). Ethanol intoxication as a function of genotype dependent responses in three inbred mice strains. Pharmacology Biochemistry and Behavior, 16, 13–15.Google Scholar

Erickson, C. (2007). The Science of Addiction. New York: W. W. Norton & Co.Google Scholar

Febo, M., Blum, K., Badgaiyan, R. D., et al. (2017a). Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z. PLoS ONE, 12, e0174774.Google Scholar

Febo, M., Blum, K., Badgaiyan, R. D., et al. (2017b). Dopamine homeostasis: brain functional connectivity in reward deficiency syndrome. Frontiers Bioscience (Landmark Edition), 22, 669–691.Google Scholar

Florence, C. S., Zhou, C., Luo, F. & Xu, L. (2016). The economic burden of prescription opioid overdose, abuse, and dependence in the United States. Medical Care, 54, 901–906.Google Scholar

Gardner, E. L. (2011). Addiction and brain reward and antireward pathways. Advances in Psychosomatic Medicine, 30, 22–60.Google Scholar

Gelernter, J., O'Malley, S., Risch, N., et al. (1991). No association between an allele at the D2 dopamine receptor gene (DRD2) and alcoholism. The Journal of American Medical Association, 266, 1801–1807.Google Scholar

Gerra, G., Somaini, L., Leonardi, C., et al. (2014). Association between gene variants and response to buprenorphine maintenance treatment. Psychiatry Research, 215, 202–207.Google Scholar

Gold, M. S., Blum, K., Febo, M., et al. (2018). Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti-reward systems. Frontiers in Bioscience (Scholar Edition), 10, 309–325.Google ScholarPubMed

Gressler, L. E., Martin, B. C., Hudson, T. J. & Painter, J. T. (2018) Relationship between concomitant benzodiazepine-opioid use and adverse outcomes among US veterans. Pain, 159, 451–459.Google Scholar

Hill, E., Han, D., Dumouchel, P., et al. (2013). Long term Suboxone™ emotional reactivity as measured by automatic detection in speech. PLoS ONE, 8, e69043.Google Scholar

Hyman, S. E. (2007). Can neuroscience be integrated into the DSM-V? Nature Reviews Neuroscience, 8(9), 725–732.Google Scholar

Johnson, M. I., Paley, C. A., Howe, T. E. & Sluka, K. A. (2015). Transcutaneous electrical nerve stimulation for acute pain. Cochrane Database Systematic Review, CD006142.Google Scholar

Joseph, Z., Victor, K. & Rimona, D. (2011). “Ego-dystonic” delusions as a predictor of dangerous behavior. Psychiatric Quaterly, 82, 113–120.Google Scholar

Kandel, D. & Kandel, E. (2015). The Gateway Hypothesis of substance abuse: developmental, biological and societal perspectives. Acta Paediatrica, 104, 130–137.CrossRefGoogle ScholarPubMed

Krebs, E. E., Gravely, A., Nugent, S., et al. (2018). Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial. The Journal of American Medical Association, 319, 872–882.Google Scholar

Loth, E., Carvalho, F. & Schumann, G. (2011). The contribution of imaging genetics to the development of predictive markers for addictions. Trends in Cognitive Sciences, 15, 436–446.Google Scholar

Lötsch, J., Skarke, C., Liefhold, J. & Geisslinger, G. (2004). Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clinical Pharmacokinetics, 43, 983–1013.Google Scholar

Makhinson, M. & Gomez-Makhinson, J. (2014). A successful treatment of buprenorphine withdrawal with the dopamine receptor agonist pramipexole. The American Journal on Addictions, 23, 475–477.Google Scholar

Matthews, S., Dwyer, R. & Snoek, A. (2017). Stigma and self-stigma in addiction. Journal of Bioethical Inquiry, 14, 275–286.Google Scholar

Moeller, S. J., Parvaz, M. A., Shumay, E., et al. (2013). Gene x abstinence effects on drug cue reactivity in addiction: multimodal evidence. Journal of Neuroscience, 33, 10027–10036.Google Scholar

Mogil, J. S. & Wilson, S. G. (1997). Nociceptive and morphine antinociceptive sensitivity of 129 and C57BL/6 inbred mouse strains: implications for transgenic knock-out studies. European Journal of Pain, 1, 293–297.Google Scholar

Palmer, R. H., Brick, L., Nugent, N. R., et al. (2015). Examining the role of common genetic variants on alcohol, tobacco, cannabis and illicit drug dependence: genetics of vulnerability to drug dependence. Addiction, 110, 530–537.Google Scholar

Pergolizzi, J. V. Jr, LeQuang, J. A., Taylor, R. Jr. & Raffa, R. B. (2018) Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances, and street heroin. Postgraduate Medicine Journal, 130, 1–8.Google Scholar

Raheb, G., Khaleghi, E., Moghanibashi-Mansourieh, A., Farhoudian, A. & Teymouri, R. (2016). Effectiveness of social work intervention with a systematic approach to improve general health in opioid addicts in addiction treatment centers. Psychology Research and Behavior Management, 9, 309–315.Google Scholar

Reilly, M. T., Noronha, A., Goldman, D. & Koob, G. F. (2017). Genetic studies of alcohol dependence in the context of the addiction cycle. Neuropharmacology, 122, 3–21.Google Scholar

Ritchie, T. & Noble, E. P. (1996). (3H) naloxone binding in the human brain: alcoholism and the TaqI A D2 dopamine receptor polymorphism. Brain Research, 718, 193–197.Google Scholar

Rudd, R. A., Seth, P., David, F. & Scholl, L. (2016). Increases in drug and opioid-involved overdose deaths – United States, 2010–2015.Morbidity and Mortality Weekly Report, 65, 1445–1452.Google Scholar

Salling, M. C. & Martinez, D. (2016). Brain stimulation in addiction. Neuropsychopharmacology, 41, 2798–2809.Google Scholar

Schoenthaler, S. J., Blum, K., Fried, L., et al. (2017). The effects of residential dual diagnosis treatment on alcohol abuse. Journal of Systems and Integrative Neuroscience, 3.CrossRefGoogle ScholarPubMed

Schreiber, A. L. (2014). Challenging pain syndromes. Physical Medicine and Rehabilitation Clinics of North America, 2, xv–xvi.Google Scholar

Severino, A. L., Shadfar, A., Hakimian, J. K., et al. (2018). Pain therapy guided by purpose and perspective in light of the opioid epidemic. Frontiers in Psychiatry, 9, 119.Google Scholar

Simpatico, T. A. (2015). Vermont responds to its opioid crisis. Preventive Medicine, 80, 10–11.Google Scholar

Smith, D. E. (2012). The process addictions and the new ASAM definition of addiction. Journal of Psychoactive Drugs, 44, 1–4.CrossRefGoogle ScholarPubMed

Smith, S. R., Deshpande, B. R., Collins, J. E., Katz, J. N. & Losina, E. (2016). Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage, 24, 962–972.Google Scholar

Stamer, U. M. & Stüber, F. (2007). Genetic factors in pain and its treatment. Current Opinion in Anaesthesiology, 20, 478–484.Google Scholar

Sussman, S. & Pakdaman, S. (2020). Appetitive needs and addiction. In Sussman, S. (Ed.) The Cambridge Handbook of Substance and Behavioral Addictions. Cambridge, UK: Cambridge University Press, pp. 3–11.Google Scholar

Szutorisz, H. & Hurd, Y. L. (2016). Epigenetic effects of cannabis exposure. Biological Psychiatry, 79, 586–594.Google Scholar

Volkow, N. D., Wise, R. A. & Baler, R. (2017). The dopamine motive system: implications for drug and food addiction. Nature Reviews Neuroscience, 18, 741–752.Google Scholar

Vonasch, A. J., Clark, C. J., Lau, S., Vohs, K. D. & Baumeister, R. F. (2017). Ordinary people associate addiction with loss of free will. Addictive Behaviors Reports, 5, 56–66.Google Scholar

Willuhn, I., Burgeno, L. M., Groblewski, P. A. & Phillips, P. E. (2014). Excessive cocaine use results from decreased phasic dopamine signaling in the striatum. Nature Neuroscience, 17, 704–709.Google Scholar

Abdulrahim, D. & Bowden-Jones, O., on behalf of the NEPTUNE Expert Group (2015). Guidance on the Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances. London: Novel Psychoactive Treatment UK Network (NEPTUNE).Google Scholar

Acciavatti, T., Lupi, M., Santacroce, R., et al. (2017). Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter-observational study. Human Psychopharmacology, 32(3), doi: 10.1002/hup.2578.Google Scholar

Addison, M., Stockdale, K., McGovern, R., et al. (2018). Exploring intersections between Novel Psychoactive Substances (NPS) and other substance use in a police custody suite setting in the North East of England. Drugs: Education, Prevention & Policy, 25(4), 313–319.Google Scholar

Alatrash, G., Majhail, N. S. & Pile, J.C. (2006). Rhabdomyolysis after ingestion of “foxy,” a hallucinogenic tryptamine derivative. Mayo Clinic Proceedings, 81(4), 550–551.Google Scholar

Alzghari, S. K., Amin, Z. M., Chau, S., et al. (2017). On the horizon: The synthetic opioid U-49900. Cureus, 9(9), e1679. http://doi.org/10.7759/cureus.1679Google Scholar

Anderson, C. Morrell, C. & Marchevsky, D. (2015). A novel psychoactive substance poses a new challenge in the management of paranoid schizophrenia. BMJ Case Reports, bcr2015209573.http://doi.org/10.1136/bcr-2015-209573Google Scholar

Anizan, S., Concheiro, M., Lehner, K. R., et al. (2016). Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. Addiction Biology, 21(2), 339–347.Google Scholar

Antia, U., Lee, H. S., Kydd, R. R., Tingle, M. D. & Russell, B. R. (2009a). Pharmacokinetics of ‘party pill’ drug N-benzylpiperazine (BZP) in healthy human participants. Forensic Science International, 186(1–3), 63–67.Google Scholar

Antia, U., Tingle, M. D. & Russell, B. R. (2009b). In vivo interactions between BZP and TFMPP (party pill drugs). The New Zealand Medical Journal, 122(1303), 29–38.Google Scholar

Araújo, A. M., Carvalho, F., Bastos Mde, L., Guedes de Pinho, P. & Carvalho, M. (2015). The hallucinogenic world of tryptamines: An updated review. Archives of Toxicology, 89(8), 1151–1173.Google Scholar

Arbo, M. D., Bastos, M. L. & Carmo, H. F. (2012). Piperazine compounds as drugs of abuse. Drug and Alcohol Dependence, 122(3), 174–185.Google Scholar

Armenian, P., Olson, A., Anaya, A., et al. (2017). Fentanyl and a novel synthetic opioid U-47700 masquerading as street “Norco” in central California: a case report. Annals of Emergency Medicine, 69(1), 87–90.Google Scholar

Armenian, P., Vo, K. T., Barr-Walker, J. & Lynch, K. L. (2018). Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review. Neuropharmacology, 134(Part A), 121–132. doi: 10.1016/j.neuropharm.2017.10.016Google Scholar

Bäckberg, M., Beck, O., Jönsson, K. H. & Helander, A. (2015). Opioid intoxications involving butyrfentanyl, 4-fluorobutyrfentanyl, and fentanyl from the Swedish STRIDA project. Clinical Toxicology (Philadelphia, Pa.), 53(7), 609–617.Google Scholar

Banks, M. L., Worst, T. J. & Sprague, J. E. (2014). Synthetic Cathinones and amphetamine analogues: What’s the rave about? The Journal of Emergency Medicine, 46(5), 632–642.Google Scholar

Barratt, M. J., Cakic, V. & Lenton, S. (2013). Patterns of synthetic cannabinoid use in Australia. Drug and Alcohol Review, 32(2), 141–146.Google Scholar

Barrios, L., Grison-Hernando, H., Boels, D., et al. (2016). Death following ingestion of methylone. International Journal of Legal Medicine, 130(2), 381–385.CrossRefGoogle ScholarPubMed

Baumann, M. H., Bukhari, M. O., Lehner, K. R., et al. (2017). Neuropharmacology of 3,4-methylenedioxypyrovalerone (MDPV), its metabolites, and related analogs. Current Topics in Behavioral Neurosciences, 32, 93–117.Google Scholar

Baumann, M. H., Clark, R. D., Budzynski, A. G., et al. (2005). N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenediox-ymethamphetamine (MDMA, or ‘Ecstasy’). Neuropsychopharmacology, 30(3), 550–560.Google Scholar

Baumeister, D., Tojo, L. M. & Tracy, D. K. (2015). Legal highs: Staying on top of the flood of novel psychoactive substances. Therapeutic Advances in Psychopharmacology, 5(2), 97–132.Google Scholar

Black, C., Setterfield, L. & Murray, L. (2016). Scottish Schools Adolescent Lifestyle and Substance Use Survey (SALSUS): Drug Use Report (2015). Scotland: Scottish Government, National Statistics publication for Scotland.Google Scholar

Blackman, S. & Bradley, R. (2017). From niche to stigma – Headshops to prison: Exploring the rise and fall of synthetic cannabinoid use among young adults. The International Journal on Drug Policy, 40, 70–77.Google Scholar

Bonar, E. E., Ashrafioun, L. & Ilgen, M. A. (2014). Synthetic cannabinoid use among patients in residential substance use disorder treatment: Prevalence, motives, and correlates. Drug and Alcohol Dependence, 143, 268–271.Google Scholar

Borek, H. A. & Holstege, C. P. (2012). Hyperthermia and multiorgan failure after abuse of “bath salts” containing 3,4-methylenedioxypyrovalerone. Annals of Emergency Medicine, 60(1), 103–105.Google Scholar

Bright, S. J., Bishop, B., Kane, R., Marsh, A. & Barratt, M. J. (2013). Kronic hysteria: Exploring the intersection between Australian synthetic cannabis legislation, the media, and drug-related harm. The International Journal on Drug Policy, 24(3), 231–237.Google Scholar

Brotherhood, A. & Sumnall, H. R. (2011). European Drug Prevention Quality Standards, Manual No 7. Lisbon: EMCDDA.Google Scholar

Brush, D. E., Bird, S. B. & Boyer, E. W. (2004). Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances. Journal of Toxicology. Clinical Toxicology, 42(2), 191–195.Google Scholar

Burns, L., Roxburgh, A., Matthews, A., et al. (2014). The rise of new psychoactive substance use in Australia. Drug Testing and Analysis, 6(7–8), 846–849.Google Scholar

Butler, R. A. & Sheridan, J. L. (2007). Highs and lows: patterns of use, positive and negative effects of benzylpiperazine-containing party pills (BZP-party pills) amongst young people in New Zealand. Harm Reduction Journal, 4, 18. doi:10.1186/1477-7517-4-18Google Scholar

Campbell, R., Starkey, F., Holliday, J., et al. (2008). An informal school-based peer-led intervention for smoking prevention in adolescence (ASSIST): A cluster randomised trial. The Lancet, 371(9624), 1595–1602.Google Scholar

Cannaert, A., Storme, J., Franz, F., Auwärter, V. & Stove, C. P. (2016). Detection and activity profiling of synthetic cannabinoids and their metabolites with a newly developed bioassay. Analytical Chemistry, 88(23), 11476–11485.Google Scholar

Carbone, P. N., Carbone, D. L., Carstairs, S. D. & Luzi, S. A. (2013). Sudden cardiac death associated with methylone use. The American Journal of Forensic Medicine and Pathology, 34(1), 26–28.CrossRefGoogle ScholarPubMed

Carhart-Harris, R. L., King, L. A. & Nutt, D. J. (2011). A web-based survey on mephedrone. Drug and Alcohol Dependence, 118(1), 19–22.Google Scholar

Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., et al. (2014). Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence, 144, 12–41.Google Scholar

Catalano, R. F., Fagan, A. A., Gavin, L. E., et al. (2012). Worldwide application of prevention science in adolescent health. The Lancet, 379(9826), 1653–1664.Google Scholar

Caudevilla-Gálligo, F., Riba, J., Ventura, M., et al. (2012). 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): Presence in the recreational drug market in Spain, pattern of use and subjective effects. Journal of Psychopharmacology, 26(7), 1026–1035.Google Scholar

Caviness, C. M., Tzilos, G., Anderson, B. J. & Stein, M. D. (2015). Synthetic cannabinoids: Use and predictors in a community sample of young adults. Substance Abuse, 36(3), 368–373.CrossRefGoogle Scholar

Cha, S.-S. & Seo, B.-K. (2018). Smartphone use and smartphone addiction in middle school students in Korea: Prevalence, social networking service, and game use. Health Psychology Open, 5(1), 2055102918755046. doi:10.1177/2055102918755046.Google Scholar

Champion, K. E., Newton, N. C., Stapinski, L. A. & Teesson, M. (2016a). Effectiveness of a universal internet-based prevention program for ecstasy and new psychoactive substances: A cluster randomized controlled trial. Addiction, 111(8), 1396–1405.Google Scholar

Champion, K. E., Teeson, M. & Newton, N. C. (2016b). Patterns and correlates of new psychoactive substance use in a sample of Australian high school students. Drug and Alcohol Review, 35(3), 338–344.Google Scholar

Cohen, K., Kapitány-Fövény, M., Mama, Y., et al. (2017). The effects of synthetic cannabinoids on executive function. Psychopharmacology (Berlin), 234(7), 1121–1134.Google Scholar

Cole, J. B., Dunbar, J. F., McIntire, S. A., Regelmann, W. E. & Slusher, T. M. (2015). Butyrfentanyl overdose resulting in diffuse alveolar hemorrhage. Pediatrics, 135(3), e740–743.Google Scholar

Cooper, Z. D. (2016). Adverse effects of synthetic cannabinoids: Management of acute toxicity and withdrawal. Current Psychiatry Reports, 18(5), 52. http://doi.org/10.1007/s11920–016-0694-1Google Scholar

Cooper, Z. D. & Haney, M. (2008). Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addiction Biology, 13(2), 188–195.Google Scholar

Corazza, O., Assi, S., Malekianragheb, S., et al. (2014). Monitoring novel psychoactive substances allegedly offered online for sale in Persian and Arabic languages. The International Journal on Drug Policy, 25(4), 724–726.CrossRefGoogle ScholarPubMed

Corazza, O., Assi, S., Simonato, P., et al. (2013). Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: The outcomes of the ReDNet project. Human Psychopharmacology, 28(4), 317–323.Google Scholar

Corazza, O. & Roman-Urrestarazu, A. (Eds.) (2017). Novel Psychoactive Substances: Policy, Economics and Drug Regulation. Berlin: Springer.Google Scholar

Corazza, O. & Roman-Urrestarazu, A. (Eds.) (2018). Handbook on Novel Psychoactive Substances. What Clinicians Should Know about NPS. New York: Routledge.Google Scholar

Corkery, J. M., Durkin, E., Elliott, S., Schifano, F. & Ghodse, A. H. (2012). The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): A brief review. Progress in Neuropsychopharmacology & Biological Psychiatry, 39(2), 259–262.Google Scholar

Csák, R., Demetrovics, Zs. & Rácz, J. (2013). Transition to injecting 3,4-methylene-dioxy-pyrovalerone (MDPV) among needle exchange program participants in Hungary. Journal of Psychopharmacology, 27(6), 559–563.Google Scholar

Csete, J., Kamarulzaman, A., Kazatchkine, M., et al. (2016). Public Health and International Drug Policy: Report of the Johns Hopkins – Lancet Commission on Drug Policy and Health. Lancet (London, England), 387(10026), 1427–1480.Google Scholar

Cunningham, S. M., Haikal, N. A. & Kraner, J. C. (2016). Fatal intoxication with acetyl fentanyl. Journal of Forensic Sciences, 61 (Supplement 1), S276–280.Google Scholar

Daldrup, T., Heller, C., Matthiesen, U., et al. (1986). [Etryptamine, a new designer drug with a fatal effect]. Zeitschrift für Rechtsmedizin, 97(1), 61–68.Google Scholar

Dargan, P. I., Albert, S. & Wood, D. M. (2010). Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM: An International Journal of Medicine, 103(11), 875–879.Google Scholar

de Boer, D., Bosman, I. J., Hidvégi, E., et al. (2001). Piperazine-like compounds: A new group of designer drugs-of-abuse on the European market. Forensic Science International, 121(1–2), 47–56.Google Scholar

Dean, B. V., Stellpflug, S. J., Burnett, A. M. & Engebretsen, K. M. (2013). 2C or not 2C: Phenethylamine designer drug review. Journal of Medical Toxicology, 9(2), 172–178.Google Scholar

Degenhardt, L. & Dunn, M. (2008). The epidemiology of GHB and ketamine use in an Australian household survey. The International Journal on Drug Policy, 19(4), 311–316.Google Scholar

Deligianni, E., Corkery, J. M., Schifano, F. & Lione, L. A. (2017). An international survey on the awareness, use, preference, and health perception of novel psychoactive substances (NPS). Human Psychopharmacology, 32(3), doi: 10.1002/hup.2581.Google Scholar

Deluca, P., Davey, Z., Corazza, O., et al. (2012). Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Progress in Neuropsychopharmacology & Biological Psychiatry, 39(2), 221–226.Google Scholar

Demetrovics, Z., Urbán, R., Nagygyörgy, K., et al. (2011). Why do you play? The development of the motives for online gaming questionnaire (MOGQ). Behavioral Research Methods, 43(3), 814–825.Google Scholar

Dick, D. & Torrance, C. (2010). Mixmag drug survey. Mixmag, 225, 44–53.Google Scholar

Domanski, K., Kleinschmidt, K. C., Schulte, J. M., et al. (2017). Two cases of intoxication with new synthetic opioid, U-47700. Clinical Toxicology (Philadelphia, Pa.), 55(1), 46–50.Google Scholar

Elliott, S. (2011). Current awareness of piperazines: Pharmacology and toxicology. Drug Testing and Analysis, 3(7–8), 430–438.Google Scholar

Elliott, S. & Smith, C. (2008). Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. Journal of Analytical Toxicology, 32(2), 172–177.Google Scholar

Elliott, S. P., Brandt, S. D. & Smith, C. (2016). The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) and implications for forensic analysis. Drug Testing and Analysis, 8(8), 875–879.Google Scholar

EMCDDA (2006). Selected Issue 3: Developments in Drug Use Within Recreational Settings. Luxembourg: Publications Office of the European Union. Available at: www.emcdda.europa.eu/system/files/publications/424/sel2006_3-en_69713.pdf [Accessed June 10, 2018]Google Scholar

EMCDDA (2016a). The Internet and Drug Markets. Luxembourg: Publications Office of the European Union. Available at: www.emcdda.europa.eu/publications/insights/internet-drug-markets [Accessed November 2, 2017]Google Scholar

EMCDDA (2016b). Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-pyrrolidinovalerophenone, α-PVP) in the framework of the Council Decision on newpsychoactive substances). Luxembourg: Publications Office of the European Union. Available at: www.emcdda.europa.eu/system/files/publications/2934/TDAK16001ENN.pdf [Accessed May 25, 2018]Google Scholar

EMCDDA (2016c). Perspectives on drugs: Health Responses to New Psychoactive Substances. Luxembourg: Publications Office of the European Union. Available at:www.emcdda.europa.eu/system/files/publications/2933/NPS%20health%20responses_POD2016.pdf [Accessed June 05, 2018]Google Scholar

EMCDDA (2017). Germany – Country Drug Report 2017. Luxembourg: Publications Office of the European Union, Available at: www.emcdda.europa.eu/system/files/publications/4528/TD0416906ENN.pdf [Accessed December 10, 2017]Google Scholar

EMCDDA-Europol (2017). Joint Report on a New Psychoactive Substance: N-phenyl-N-[1-(2-Phenylethyl)piperidin-4-yl]-furan-2-carboxamide (furanylfentanyl). Luxembourg: Publications Office of the European Union, Available at: www.emcdda.europa.eu/system/files/publications/4682/JOINT_REPORT_furanylfentanyl_web.pdf [Accessed June 1, 2018]Google Scholar

ESPAD Group (2016). ESPAD Report 2015 – Results from the European School Survey Project on Alcohol and Other Drugs. Luxembourg: Publications Office of the European Union. Available at: www.espad.org/sites/espad.org/files/ESPAD_report_2015.pdf [Accessed October 17, 2017]Google Scholar

Euro-DEN (2015). Guidelines on when to call the Emergency Services 112 for unwell recreational drug users. Lisbon: EMCDDA.Google Scholar

Evenepoel, T. (2015). Drug helplines, online health and NPS. Presentation at the Health responses to NPS EMCDDA expert meeting, October 28–29, 2015, EMCDDA, Lisbon. Available at: www.emcdda.europa.eu/events/meetings/2015/nps-health-responses [Accessed December 20, 2017]Google Scholar

Every-Palmer, S. (2011). Synthetic cannabinoid JWH-018 and psychosis: An explorative study. Drug and Alcohol Dependence, 117(2–3), 152–157.Google Scholar

Fantegrossi, W. E., Harrington, A. W., Kiessel, C. L., et al. (2006). Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacology, Biochemistry and Behavior, 83(1), 122–129.Google Scholar

Fantegrossi, W. E., Moran, J. H., Radominska-Pandya, A. & Prather, P. L. (2014). Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity? Life Sciences, 97(1), 45–54.Google Scholar

Fattore, L. & Fratta, W. (2011). Beyond THC: The new generation of cannabinoid designer drugs. Frontiers in Behavioral Neuroscience, 5, 60. doi: 10.3389/fnbeh.2011.00060.Google Scholar

Fels, H., Krueger, J., Sachs, H., et al. (2017). Two fatalities associated with synthetic opioids: AH-7921 and MT-45. Forensic Science International, e30–e35. doi: 10.1016/j.forsciint.2017.04.003.Google Scholar

Forsyth, A. J. M. (2012). Virtually a drug scare: Mephedrone and the impact of the Internet on drug news transmission. The International Journal on Drug Policy, 23(3), 198–209.Google Scholar

Gee, P., Richardson, S., Woltersdorf, W. & Moore, G. (2005). Toxic effects of BZP-based herbal party pills in humans: A prospective study in Christchurch, New Zealand. The New Zealand Medical Journal, 118(1227), U1784.Google Scholar

German, C. L., Fleckenstein, A. E. & Hanson, G. R. (2014). Bath salts and synthetic cathinones: An emerging designer drug phenomenon. Life Sciences, 97(1), 2–8.Google Scholar

Gilani, F. (2016). Novel psychoactive substances: The rising wave of “legal highs”. The British Journal of General Practice, 66(642), 8–9.Google Scholar

Ginsburg, B. C., McMahon, L. R., Sanchez, J. J. & Javors, M. A. (2012). Purity of synthetic cannabinoids sold online for recreational use. Journal of Analytical Toxicology, 36(1), 66–68.Google Scholar

Gołembiowska, K., Jurczak, A., Kamińska, K., Noworyta-Sokołowska, K. & Górska, A. (2016). Effect of some psychoactive drugs used as “legal highs” on brain neurotransmitters. Neurotoxicity Research, 29, 394–407.Google Scholar

Gregg, R. A., Tallarida, C. S., Reitz, A., McCurdy, C. & Rawls, S. M. (2013). Mephedrone (4-methylmethcathinone), a principal constituent of psychoactive bath salts, produces behavioral sensitization in rats. Drug and Alcohol Dependence, 133(2), 746–750.Google Scholar

Griswold, M. K., Chai, P. R., Krotulski, A. J., et al. (2017). A novel oral fluid assay (LC-QTOF-MS) for the detection of fentanyl and clandestine opioids in oral fluid after reported heroin overdose. Journal of Medical Toxicology, 13(4), 287–292.Google Scholar

Guerrieri, D., Rapp, E., Roman, M., Druid, H. & Kronstrand, R. (2017). Postmortem and toxicological findings in a series of furanylfentanyl-related deaths. Journal of Analytical Toxicology, 41(3), 242–249.Google Scholar

Guirguis, A., Corkery, J., Stair, J., et al. (2015). Survey of knowledge of legal highs (novel psychoactivesubstances) amongst London pharmacists. Drugs and Alcohol Today, 15(2), 93–99.Google Scholar

Gunderson, E. W., Haughey, H. M., Ait-Daoud, N., Joshi, A. S. & Hart, C. L. (2014). A Survey of synthetic cannabinoid consumption by current cannabis users. Substance Abuse, 35(2), 184–189.Google Scholar

Gustavsson, D. & Escher, C. (2009). [Mephedrone-Internet drug which seems to have come and stay. Fatal cases in Sweden have drawn attention to previously unknown substance]. Lakartidningen, 106(43), 2769–2771.Google Scholar

Hawk, K. F., Vaca, F. E. & D’Onofrio, G. (2015). Reducing fatal opioid overdose: Prevention, treatment and harm reduction strategies. The Yale Journal of Biology and Medicine, 88(3), 235–245.Google Scholar

Health and Social Care Information Centre (2015). Smoking, Drinking and Drug Use among Young People in England – 2013. London: Health and Social Care Information Centre.Google Scholar

Helander, A., Bäckberg, M. & Beck, O. (2014). MT-45, a new psychoactive substance associated with hearing loss and unconsciousness. Clinical Toxicology (Philadelphia, Pa.), 52(8), 901–904.Google Scholar

Helander, A., Bäckberg, M. & Beck, O. (2016). Intoxications involving the fentanyl analogs acetylfentanyl, 4-methoxybutyrfentanyl and furanylfentanyl: Results from the Swedish STRIDA project. Clinical Toxicology (Philadelphia, Pa.), 54(4), 324–332.Google Scholar

Helander, A., Bradley, M., Hasselblad, A., et al. (2017). Acute skin and hair symptoms followed by severe, delayed eye complications in subjects using the synthetic opioid MT-45. The British Journal of Dermatology, 176(4), 1021–1027.Google Scholar

Hermanns-Clausen, M., Kneisel, S., Szabo, B. & Auwärter, V. (2013). Acute toxicity due to the confirmed consumption of synthetic cannabinoids: Clinical and laboratory findings. Addiction, 108(3), 534–544.Google Scholar

Hess, C., Stockhausen, S., Kernbach-Wighton, G. & Madea, B. (2015). Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids? Forensic Science International, 257, e6–11. doi: 10.1016/j.forsciint.2015.08.012.Google Scholar

Ikeda, A., Sekiguchi, K., Fujita, K., Yamadera, H. & Koga, Y. (2005). 5-methoxy-N,N-diisopropyltryptamine-induced flashbacks. The American Journal of Psychiatry, 162(4), 815.Google Scholar

Itokawa, M., Iwata, K., Takahashi, M., et al. (2007). Acute confusional state after designer tryptamine abuse. Psychiatry and Clinical Neurosciences, 61(2), 196–199.Google Scholar

Jan, R. K., Lin, J. C., Lee, H., et al. (2010). Determining the subjective effects of TFMPP in human males. Psychopharmacology (Berlin), 211(3), 347–353.Google Scholar

Javadi-Paydar, M., Nguyen, J. D., Vandewater, S. A., Dickerson, T. J. & Taffe, M. A. (2018). Locomotor and reinforcing effects of pentedrone, pentylone and methylone in rats. Neuropharmacology, 134(Part A), 57–64. doi: 10.1016/j.neuropharm.2017.09.002.Google Scholar

Jebadurai, J. K. (2012). Qualitative research of online drug misuse communities with reference to the novel psychoactive substances. Doctoral Thesis at the University of Hertfordshire.Google Scholar

Jones, M. J., Hernandez, B. S., Janis, G. C. & Stellpflug, S. J. (2017). A case of U-47700 overdose with laboratory confirmation and metabolite identification. Clinical Toxicology (Philadelphia, Pa.), 55(1), 55–59.Google Scholar

Joseph, A. M., Manseau, M. W., Lalane, M., Rajparia, A. & Lewis, C. F. (2017). Characteristics associated with synthetic cannabinoid use among patients treated in a public psychiatric emergency setting. The American Journal of Drug and Alcohol Abuse, 43(1), 117–122.Google Scholar

Jovel, A., Felthous, A. & Bhattacharyya, A. (2014). Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT. Journal of Forensic Sciences, 59(3), 844–846.Google Scholar

Kalasho, A. & Vibe Nielsen, S. (2016). 5-MeO-DALT; a novel designer drug on the market causing acute delirium and rhabdomyolysis. Acta Anaesthesiologica Scandinavica, 60(9), 1332–1336.Google Scholar

Kapitány-Fövény, M. & Demetrovics, Z. (2017). Utility of Web search query data in testing theoretical assumptions about mephedrone. Human Psychopharmacology, 32(3). doi: 10.1002/hup.2620Google Scholar

Kapitány-Fövény, M., Farkas, J., Csorba, J., Szabó, T. & Demetrovics, Z. (2013a). Különbségek a szintetikus kannabinoidok és a kannabisz szubjektív hatásaiban, a használati mintázatban és a használat okaiban. Magyar Addiktológiai Társaság IX. Országos Kongresszus, Siófok, 2013.11.21-2013.11.23, p. 25.Google Scholar

Kapitány-Fövény, M., Farkas, J., Pataki, P. A., et al. (2017). Novel psychoactive substance use among treatment-seeking opiate users: The role of life events and psychiatric symptoms. Human Psychopharmacology, 32(3), doi: 10.1002/hup.2602Google Scholar

Kapitány-Fövény, M., Kertész, M., Winstock, A., et al. (2013b). Substitutional potential of mephedrone: An analysis of the subjective effects. Human Psychopharmacology, 28(4), 308–316.Google Scholar

Kapitány-Fövény, M., Vagdalt, E., Ruttkay, Z., et al. (2018). Potential of an interactive drug prevention mobile phone app (Once Upon a High): Questionnaire study among students.. JMIR Serious Games, 6(4), e19. doi: 10.2196/games.9944Google Scholar

Karila, L., Billieux, J., Benyamina, A., Lançon, C. & Cottencin, O. (2016). The effects and risks associated to mephedrone and methylone in humans: A review of the preliminary evidences. Brain Research Bulletin, 126(Part 1), 61–67.Google Scholar

Karila, L., Lafaye, G., Scocard, A., Cottencin, O. & Benyamina, A. (2018). MDPV and α-PVP use in humans: The twisted sisters. Neuropharmacology, 134(Part A), 65–72.Google Scholar

Karila, L., Megarbane, B., Cottencin, O. & Lejoyeux, M. (2015). Synthetic cathinones: A new public health problem. Current Neuropharmacology, 13(1), 12–20.Google Scholar

Katselou, M., Papoutsis, I., Nikolaou, P., Spiliopoulou, C. & Athanaselis, S. (2015). AH-7921: The list of new psychoactive opioids is expanded. Forensic Toxicology, 33(2), 195–201.Google Scholar

Katz, K. D., Leonetti, A. L., Bailey, B. C., et al. (2016). Case series of synthetic cannabinoid intoxication from one toxicology center. Western Journal of Emergency Medicine, 17(3), 290–294.Google Scholar

Kehr, J., Ichinose, F., Yoshitake, S., et al. (2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. British Journal of Pharmacology, 164(8), 1949–1958.Google Scholar

Kelly, B. C., Wells, B. E., Pawson, M., et al. (2013). Novel psychoactive drug use among younger adults involved in US nightlife scenes. Drug and Alcohol Review, 32(6), 10.1111/dar.12058. http://doi.org/10.1111/dar.12058Google Scholar

Kempf, C., Llorca, P-M., Pizon, F., Brousse, G. & Flaudias, V. (2017). What’s new in addiction prevention in young people: A literature review of the last years of research. Frontiers in Psychology, 8, 1131. doi:10.3389/fpsyg.2017.01131.Google Scholar

Kersten, B. P. & McLaughlin, M. E. (2015). Toxicology and management of novel psychoactive drugs. Journal of Pharmacy Practice, 28(1), 50–65.Google Scholar

Kesha, K., Boggs, C. L., Ripple, M. G., et al. (2013). Methylenedioxypyrovalerone ("bath salts"), related death: Case report and review of the literature. Journal of Forensic Sciences, 58(6), 1654–1659.Google Scholar

Kikura-Hanajiri, R., Kawamura, N. U. & Goda, Y. (2014). Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan. Drug Testing and Analysis, 6(7–8), 832–839.Google Scholar

Kjellgren, A., Jacobsson, K. & Soussan, C. (2016). The quest for well-being and pleasure: Experiences of the novel synthetic opioids AH-7921 and MT-45, as reported by anonymous users online. Journal of Addiction Research & Therapy, 7, 287. doi: 10.4172/2155-6105.1000287Google Scholar

Kovács, K., Tóth, A. R. & Kereszty, E. M. (2012). [A new designer drug: methylone related death]. Orvosi Hetilap, 153(7), 271–276.Google Scholar

Kovaleva, J., Devuyst, E., De Paepe, P. & Verstraete, A. (2008). Acute chlorophenylpiperazine overdose: A case report and review of the literature. Therapeutic Drug Monitoring, 30(3), 394–398.Google Scholar

Labay, L. M., Caruso, J. L., Gilson, T. P., et al. (2016). Synthetic cannabinoid drug use as a cause or contributory cause of death. Forensic Science International, 260, 31–39.Google Scholar

Larabi, I. A., Martin, M., Etting, I., et al. (2018). Drug-facilitated sexual assault (DFSA) involving 4-methylethcathinone (4-MEC), 3,4-Methylenedioxypyrovalerone (MDPV), and doxylamine highlighted by hair analysis. Drug Testing and Analysis. doi: 10.1002/dta.2377.Google Scholar

Lea, T., Reynolds, R. & De Wit, J. (2011). Mephedrone use among same-sex attracted young people in Sydney, Australia. Drug and Alcohol Review, 30(4), 438–440.Google Scholar

Lee, H. P., Chae, P. K., Lee, H. S. & Kim, Y. K. (2007). The five-factor gambling motivation model. Psychiatry Research, 150(1), 21–32.Google Scholar

Lee, H., Kim, J. W. & Choi, T. Y. (2017). Risk factors for smartphone addiction in Korean adolescents: Smartphone use patterns. Journal of Korean Medical Science, 32(10), 1674–1679.Google Scholar

Lin, J. C., Bangs, N., Lee, H., Kydd, R. R. & Russell, B. R. (2009). Determining the subjective and physiological effects of BZP on human females. Psychopharmacology, 207(3), 439–446.Google Scholar

Lin, J. C., Jan, R. K., Kydd, R. R. & Russell, B. R. (2011). Subjective effects in humans following administration of party pill drugs BZP and TFMPP alone and in combination. Drug Testing and Analysis, 3(9), 582–585.Google Scholar

Lozier, M. J., Boyd, M., Stanley, C., et al. (2015). Acetyl fentanyl, a novel fentanyl analog, causes 14 overdose deaths in Rhode Island, March–May 2013. Journal of Medical Toxicology, 11(2), 208–217.Google Scholar

Lusthof, K. J., Oosting, R., Maes, A., et al. (2011). A case of extreme agitation and death after the use of mephedrone in The Netherlands. Forensic Science International, 206(1–3), e93–95. doi: 10.1016/j.forsciint.2010.12.014.Google Scholar

Majeed-Ariss, R., Baildam, E., Campbell, M., et al. (2015). Apps and adolescents: A systematic review of adolescents' use of mobile phone and tablet apps that support personal management of their chronic or long-term physical conditions. Journal of Medical Internet Research, 17(12), e287. doi: 10.2196/jmir.5043Google Scholar

Marrinan, S., Roman-Urrestarazu, A., Naughton, D., et al. (2017). Hair analysis for the detection of drug use-is there potential for evasion? Human Psychopharmacology, 32(3), doi: 10.1002/hup.2587.Google Scholar

Martínez-Clemente, J., López-Arnau, R., Carbó, M., et al. (2013). Mephedrone pharmacokinetics after intravenous and oral administration in rats: Relation to pharmacodynamics. Psychopharmacology, 229(2), 295–306.Google Scholar

Martinotti, G., Lupi, M., Acciavatti, T., et al. (2014). Novel psychoactive substances in young adults with and without psychiatric comorbidities. BioMed Research International, 2014, 815424. doi: 10.1155/2014/815424.Google Scholar

Martinotti, G., Lupi, M., Carlucci, L., et al. (2015). Novel psychoactive substances: Use and knowledge among adolescents and young adults in urban and rural areas. Human Psychopharmacology, 30(4), 295–301.Google Scholar

McCall, H., Adams, N., Mason, D. & Willis, J. (2015). What is chemsex and why does it matter? BMJ, 351, h5790. doi: 10.1136/bmj.h5790Google Scholar

McIntyre, I. M., Trochta, A., Gary, R. D., Malamatos, M. & Lucas, J. R. (2015). acute acetyl fentanyl fatality: A case report with postmortem concentrations. Journal of Analytical Toxicology, 39(6), 490–494.Google Scholar

McIntyre, I. M., Trochta, A., Gary, R. D., Wright, J. & Mena, O. (2016). An acute butyr-fentanyl fatality: A case report with postmortem concentrations. Journal of Analytical Toxicology, 40(2), 162–166.CrossRefGoogle ScholarPubMed

Mdege, N. D., Meader, N., Lloyd, C., Parrott, S. & McCambridge, J. (2017). The Novel Psychoactive Substances in the UK Project: Empirical and Conceptual Review Work to Produce Research Recommendations. Southampton (UK): NIHR Journals Library. Available at: www.ncbi.nlm.nih.gov/pubmedhealth/PMH0095704/ [Accessed December 20, 2017]Google Scholar

Meader, N., Mdege, N. & McCambridge, J. (2018). The public health evidence-base on novel psychoactive substance use: Scoping review with narrative synthesis of selected bodies of evidence. Journal of Public Health (Oxford, England). doi: 10.1093/pubmed/fdy016Google Scholar

Meltzer, P. C., Butler, D., Deschamps, J. R. & Madras, B. K. (2006). 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogs. A promising class of monoamine uptake inhibitors. Journal of Medicinal Chemistry, 49(4), 1420–1432.Google Scholar

Miliano, C., Serpelloni, G., Rimondo, C., et al. (2016). Neuropharmacology of New Psychoactive Substances (NPS): Focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Frontiers in Neuroscience, 10, 153. http://doi.org/10.3389/fnins.2016.00153Google Scholar

Miller, M. L., Creehan, K. M., Angrish, D., et al. (2013). Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). Drug and Alcohol Dependence, 127(1–3), 248–253.Google Scholar

Miller, J. M., Stogner, J. M., Miller, B. L. & Blough, S. (2018). Exploring synthetic heroin: Accounts of acetyl fentanyl use from a sample of dually diagnosed drug offenders. Drug and Alcohol Review, 37(1), 121–127.Google Scholar

Ministry of Health – New Zealand (2012). Regulatory impact statement, new regulatory regime for psychoactive substances. Wellington, New Zealand: The Treasury. Available at: www.health.govt.nz/about-ministry/legislation-and-regulation/regulatory-impact-statements/new-regulatory-regime-psychoactive-substances. [Accessed October 16, 2017]Google Scholar

Moore, K., Dargan, P. I., Wood, D. M. & Measham, F. (2013). Do novel psychoactive substances displace established club drugs, supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy and cocaine. European Addiction Research, 19(5), 276–282.Google Scholar

Morano, R. A., Spies, C., Walker, F. B. & Plank, S. M. (1993). Fatal intoxication involving etryptamine. Journal of Forensic Sciences, 38(3), 721–725.Google Scholar

Móró, L. & Rácz, J. (2013). Online drug user-led harm reduction in Hungary: A review of “Daath”. Harm Reduction Journal, 10, 18. doi: 10.1186/1477-7517-10-18.Google Scholar

Murphy, D. L., Lesch, K. P., Aulakh, C. S. & Pigott, T. A. (1991). Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacological Reviews, 43(4), 527–552.Google Scholar

Murray, B. L., Murphy, C. M. & Beuhler, M. C. (2012). Death following recreational use of designer drug “bath salts” containing 3,4-methylenedioxypyrovalerone (MDPV). Journal of Medical Toxicology, 8(1), 69–75.Google Scholar

Nagai, H., Saka, K., Nakajima, M., et al. (2014). Sudden death after sustained restraint following self-administration of the designer drug α-pyrrolidinovalerophenone. International Journal of Cardiology, 172(1), 263–265.Google Scholar

Negrei, C., Galateanu, B., Stan, M., et al. (2017). Worldwide legislative challenges related to psychoactive drugs. DARU Journal of Pharmaceutical Sciences, 25, 14. http://doi.org/10.1186/s40199–017-0180-2Google Scholar

Nurmedov, S., Yilmaz, O., Darcin, A. E., Noyan, O. C. & Dilbaz, N. (2015). Frequency of synthetic cannabinoid use and its relationship with socio-demographic characteristics and treatment outcomes in alcohol- and substance-dependent inpatients: A retrospective study. Klinik Psikofarmakoloji Bulteni – Bulletin of Clinical Psychopharmacology, 25(4), 348–354.Google Scholar

Nutt, D. (2015). Open letter to David Cameron, Prime Minister. www.independent.co.uk/news/uk/home-news/former-government-drugs-adviser-professor-david-nutt-writes-to-pm-arguing-against-banning-legal-10374433.htmlGoogle Scholar

Oei, A. C. & Patterson, M. D. (2013). Enhancing cognition with video games: A multiple game training study, Geng, J. J. (Ed.). PLoS ONE, 8(3), e58546. doi:10.1371/journal.pone.0058546.Google Scholar

Ott, J. (2001). Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine. Journal of Psychoactive Drugs, 33(4), 403–407.Google Scholar

Paglia-Boak, A., Mann, R. E., Adlaf, E. M. & Rehm, J. (2009). Drug Use among Ontario Students, 1977–2009: Detailed OSDUHS Findings. Toronto, Ontario: Centre for Addiction and Mental Health. Available at: http://odesi1.scholarsportal.info/documentation/PHIRN/OSDUHS/Highlights_DrugReport_2009OSDUHS_Final_Web.pdf [Accessed: May 15, 2018]Google Scholar

Paksi, B., Magi, A., Felvinczi, K. & Demetrovics, Zs. (2016). The prevalence of new psychoactive substances in Hungary – Based on a general population survey dealing with addiction related problems (OLAAP 2015). IV. International Conference on Novel Psychoactive Substances (NPS). Budapest, May 30–31, 2016.Google Scholar

Palamar, J. J., Martins, S. S., Su, M. K. & Ompad, D.C. (2015). Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting. Drug and Alcohol Dependence, 156, 112–119.Google Scholar

Palamar, J. J., Su, M. K. & Hoffman, R. S. (2016). Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011–2014. The American Journal of Drug and Alcohol Abuse, 42(1), 39–47.Google Scholar

Palma-Conesa, Á. J., Ventura, M., Galindo, L., et al. (2017). Something new about something old: A 10-year follow-up on classical and new psychoactive tryptamines and results of analysis. Journal of Psychoactive Drugs, 49(4), 297–305.Google Scholar

Papaseit, E., Olesti, E., de la Torre, R., Torrens, M. & Farré, M. (2017). Mephedrone concentrations in cases of clinical intoxication. Current Pharmaceutical Design. doi: 10.2174/1381612823666170704130213.Google Scholar

Papaseit, E., Pérez-Mañá, C., Mateus, J.-A., et al. (2016). Human pharmacology of mephedrone in comparison with MDMA. Neuropsychopharmacology, 41(11), 2704–2713.Google Scholar

Papsun, D., Krywanczyk, A., Vose, J. C., Bundock, E. A. & Logan, B. K. (2016). Analysis of MT-45, a novel synthetic opioid, in human whole blood by LC-MS-MS and its identification in a drug-related death. Journal of Analytical Toxicology, 40(4), 313–317.Google Scholar

Patrick, M. E., O’Malley, P. M., Kloska, D. D., et al. (2016). Novel psychoactive substance use by US adolescents: Characteristics associated with use of synthetic cannabinoids and synthetic cathinones. Drug and Alcohol Review, 35(5), 586–590.Google Scholar

Pearson, J. M., Hargraves, T. L., Hair, L. S., et al. (2012). Three fatal intoxications due to methylone. Journal of Analytical Toxicology, 36(6), 444–451.Google Scholar

Penders, T. M., Gestring, R. E. & Vilensky, D. A. (2012). Intoxication delirium following use of synthetic cathinone derivatives. The American Journal of Drug and Alcohol Abuse, 38(6), 616–617.Google Scholar

Penney, J., Dargan, P. I., Padmore, J., Wood, D. M. & Norman, I. J. (2016). Epidemiology of adolescent substance use in London schools. QJM: An International Journal of Medicine, 109(6), 405–409.Google Scholar

Péterfi, A., Tarján, A., Horváth, G. C., Csesztregi, T. & Nyírády, A. (2014). Changes in patterns of injecting drug use in Hungary: A shift to synthetic cathinones. Drug Testing and Analysis, 6(7–8), 825–831.Google Scholar

Pintori, N., Loi, B. & Mereu, M. (2017). Synthetic cannabinoids: The hidden side of Spice drugs. Behavioral Pharmacology, 28(6), 409–419.Google Scholar

Poklis, J., Poklis, A., Wolf, C., et al. (2016). Two fatal intoxications involving butyryl fentanyl. Journal of Analytical Toxicology, 40(8), 703–708.Google Scholar

Potocka-Banaś, B., Janus, T., Majdanik, S., et al. (2017). Fatal intoxication with α-PVP, a synthetic cathinone derivative. Journal of Forensic Sciences, 62(2), 553–556.Google Scholar

Prekupec, M. P., Mansky, P. A. & Baumann, M. H. (2017). Misuse of novel synthetic opioids: A deadly new trend. Journal of Addiction Medicine, 11(4), 256–265.Google Scholar

Prosser, J. M. & Nelson, L. S. (2012). The toxicology of bath salts: A review of synthetic cathinones. Journal of Medical Toxicology, 8(1), 33–42.Google Scholar

Ralphs, R. & Gray, P. (2017). New psychoactive substances: New service provider challenges. Drugs: Education, Prevention and Policy, 25(4), 301–312.Google Scholar

Ralphs, R., Williams, L., Askew, R. & Norton, A. (2017). Adding Spice to the Porridge: The development of a synthetic cannabinoid market in an English prison. The International Journal on Drug Policy, 40, 57–69.Google Scholar

Rambaran, K. A., Fleming, S. W., An, J., et al. (2017). U-47700: A clinical review of the literature. The Journal of Emergency Medicine, 53(4), 509–519.Google Scholar

RAND (EUROPE) (2016). The role of the ‘dark’ web in the trade of illicit drugs. Research brief. Available at: www.rand.org/content/dam/rand/pubs/research_briefs/RB9900/RB9925/RAND_RB9925.pdf [Accessed: June 06, 2018]Google Scholar

Reuter, P. & Pardo, B. (2017). Can new psychoactive substances be regulated effectively? An assessment of the British Psychoactive Substances Bill. Addiction, 112(1), 25–31.Google Scholar

Rodgman, C. J. C., Verrico, C. D., Worthy, R. B. & Lewis, E. E. (2014). Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone. The Primary Care Companion for CNS Disorders, 16(4), 10.4088/PCC.13l01594. http://doi.org/10.4088/PCC.13l01594Google Scholar

Romanek, K., Stenzel, J., Schmoll, S., et al. (2017). Synthetic cathinones in Southern Germany – Characteristics of users, substance-patterns, co-ingestions, and complications. Clinical Toxicology (Philadelphia, Pa.), 55(6), 573–578.Google Scholar

Sanders, B., Lankenau, S. E., Bloom, J. J. & Hathazi, D. (2008). “Research Chemicals”: Tryptamine and phenethylamine use among high-risk youth. Substance Use & Misuse, 43(3–4), 389–402.Google Scholar

Schep, L. J., Slaughter, R. J., Hudson, S., Place, R. & Watts, M. (2015). Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Human & Experimental Toxicology, 34(5), 557–560.Google Scholar

Schep, L. J., Slaughter, R. J., Vale, J. A., Beasley, D. M. & Gee, P. (2011). The clinical toxicology of the designer party pills benzylpiperazine and trifluoromethylphenylpiperazine. Clinical Toxicology (Philadelphia, Pa.), 49(3), 131–141.Google Scholar

Schifano, F., Orsolini, L., Duccio Papanti, G. & Corkery, J. M. (2015). Novel psychoactive substances of interest for psychiatry. World Psychiatry, 14(1), 15–26.Google Scholar

Schindler, C. W., Thorndike, E. B., Suzuki, M., Rice, K. C. & Baumann, M. H. (2016). Pharmacological mechanisms underlying the cardiovascular effects of the “bath salt” constituent 3,4‐methylenedioxypyrovalerone (MDPV). British Journal of Pharmacology, 173(24), 3492–3501.Google Scholar

Schneir, A., Metushi, I. G., Sloane, C., Benaron, D. J. & Fitzgerald, R. L. (2017). Near death from a novel synthetic opioid labeled U-47700: Emergence of a new opioid class. Clinical Toxicology (Philadelphia, Pa.), 55(1), 51–54.Google Scholar

Shanks, K. G. & Behonick, G. S. (2016). Death after use of the synthetic cannabinoid 5F-AMB. Forensic Science International, 262, e21–24, doi: 10.1016/j.forsciint.2016.03.004.Google Scholar

Shanks, K. G., Clark, W. & Behonick, G. (2016). Death associated with the use of the synthetic cannabinoid ADB-FUBINACA. Journal of Analytical Toxicology, 40(3), 236–239.Google Scholar

Shimizu, E., Watanabe, H., Kojima, T., et al. (2007). Combined intoxication with methylone and 5-MeO-MIPT. Progress in Neuropsychopharmacology & Biological Psychiatry, 31(1), 288–291.Google Scholar

Siddiqi, S., Verney, C., Dargan, P. & Wood, D. M. (2015). Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45. Clinical Toxicology (Philadelphia, Pa.), 53(1), 54–59.Google Scholar

Simonato, P., Bersani, F. S., Santacroce, R., et al. (2017). Can mobile phone technology support a rapid sharing of information on novel psychoactive substances among health and other professionals internationally? Human Psychopharmacology, 32(3). doi: 10.1002/hup.2580Google Scholar

Simonato, P., Corazza, O.,  Santonastaso, P.,  et al. (2013). Novel psychoactive substances as a novel challenge for health professionals; results from an Italian survey. Human Psychopharmacology, 28(4), 324–331.Google Scholar

Sindicich, N. & Burns, L. (2012). Australian trends in ecstasy and related drug markets 2012: Findings from the Ecstasy and Related Drugs Reporting System (EDRS). Australian Drug Trends Series No.100. National Drug and Alcohol Research Centre, University of New South Wales. Available at: https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/EDRS%202012%20national%20report%20FINAL.pdf [Accessed: October 16, 2017]Google Scholar

Sivagnanam, K., Chaudari, D., Lopez, P., Sutherland, M. E. & Ramu, V. K. (2013). “Bath salts” induced severe reversible cardiomyopathy. The American Journal of Case Reports, 14, 288–291.Google Scholar

Smith, K. & Flatley, J. (2011). Drug Misuse Declared: Findings from the 2010/2011 British Crime Survey England and Wales. UK: Home Office.Google Scholar

Smith, S. W. & Garlich, F. M. (2013). Availability and supply of novel psy-choactive substances. In Dargan, P. I. & Wood, D. M. (Eds.), Novelpsychoactive Substances: Classification, Pharmacology and Toxicology. Elsevier, UK: Academic Press, pp. 55–86.Google Scholar

Smolinske, S. C., Rastogi, R. & Schenkel, S. (2005). Foxy methoxy: A new drug of abuse. Journal of Medical Toxicology, 1(1), 22–25.Google Scholar

Smyth, B. P., James, P., Cullen, W. & Darker, C. (2015). “So prohibition can work?” Changes in use of novel psychoactive substances among adolescents attending a drug and alcohol treatment service following a legislative ban. The International Journal on Drug Policy, 26(9), 887–889.Google Scholar

Smyth, B. P., Lyons, S. & Cullen, W. (2017). Decline in new psychoactive substance use disorders following legislation targeting headshops: Evidence from national addiction treatment data. Drug and Alcohol Review, 36(5), 609–617.Google Scholar

Soussan, C. & Kjellgren, A. (2016). The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations. The International Journal of Drug Policy, 32, 77–84.Google Scholar

Soussan, C., Andersson, M. & Kjellgren, A. (2018). The diverse reasons for using Novel Psychoactive Substances – A qualitative study of the users’ own perspectives. The International Journal on Drug Policy, 52, 71–78.Google Scholar

Spaderna, M., Addy, P. H. & D’Souza, D. C. (2013). Spicing thing up: Synthetic cannabinoids. Psychopharmacology, 228(4), 525–540.Google Scholar

Spiller, H. A., Ryan, M. L., Weston, R. G. & Jansen, J. (2011). Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clinical Toxicology (Philadelphia, Pa.), 49(6), 499–505.Google Scholar

Srisung, W., Jamal, F. & Prabhakar, S. (2015). Synthetic cannabinoids and acute kidney injury. Proceedings (Baylor University Medical Center), 28(4), 475–477.Google Scholar

Stanciu, C. N., Penders, T. M., Gnanasegaram, S. A., et al. (2017). The behavioral profile of methylenedioxypyrovalerone (MDPV) and α-pyrrolidinopentiophenone (PVP) – A systematic review. Current Drug Abuse Reviews. doi: 10.2174/1874473710666170321122226.Google Scholar

Stanley, J. L., Mogford, D. V., Lawrence, R. J. & Lawrie, S. M. (2016). Use of novel psychoactive substances by inpatients on general adult psychiatric wards. BMJ Open, 6(5), e009430. http://doi.org/10.1136/bmjopen-2015-009430Google Scholar

Štefková, K., Židková, M., Horsley, R. R., et al. (2017). Pharmacokinetic, ambulatory, and hyperthermic effects of 3,4-methylenedioxy-N-methylcathinone (methylone) in rats. Frontiers in Psychiatry, 8, 232. http://doi.org/10.3389/fpsyt.2017.00232Google Scholar

Stevens, A., Fortson, R., Measham, F. & Sumnall, H. (2015). ‘Legally flawed, scientifically problematic, potentially harmful: The UK Psychoactive Substance Bill’. International Journal of Drug Policy, 26(12), 1167–1170.Google Scholar

Stogner, J. M. (2014). The potential threat of acetyl fentanyl: Legal issues, contaminated heroin, and acetyl fentanyl "disguised" as other opioids. Annals of Emergency Medicine, 64(6), 637–639.Google Scholar

Strassman, R. J. (1996). Human psychopharmacology of N,N-dimethyltryptamine. Behavioural Brain Research, 73(1–2), 121–124.Google Scholar

Stratton, S. J., Rogers, C., Brickett, K. & Gruzinski, G. (2001). Factors associated with sudden death of individuals requiring restraint for excited delirium. The American Journal of Emergency Medicine, 19(3), 187–191.Google Scholar

Sykutera, M., Cychowska, M. & Bloch-Boguslawska, E. (2015). A fatal case of pentedrone and α-pyrrolidinovalerophenone poisoning. Journal of Analytical Toxicology, 39(4), 324–329.Google Scholar

Takase, I., Koizumi, T., Fujimoto, I., Yanai, A. & Fujimiya, T. (2016). An autopsy case of acetyl fentanyl intoxication caused by insufflation of 'designer drugs'. Legal Medicine (Tokyo), 21, 38–44.Google Scholar

Tanaka, E., Kamata, T., Katagi, M., Tsuchihashi, H. & Honda, K. (2006). A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy. Forensic Science International, 163(1–2), 152–154.Google Scholar

Tancer, M. E. & Johanson, C. E. (2001). The subjective effects of MDMA and mCPP in moderate MDMA users. Drug and Alcohol Dependence, 65(1), 97–101.Google Scholar

TEDI (Trans European Drug Information) (2013). 2nd TEDI Trend Report, Nightlife Empowerment and Well-Being Information Project (NEWIP). Available at: http://fileserver.idpc.net/library/Tedi_trend_report_feb2013.pdf [Accessed June 05, 2018]Google Scholar

Teske, J., Weller, J. P., Fieguth, A., et al. (2010). Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. Journal of Chromatography, B. Analytical Technologies in the Biomedical and Life Sciences, 878(27), 2659–2663.Google Scholar

Thammongkolchai, T., Termsarasab, P., Alkhachroum, A., et al. (2015). 5-Meo-DALT-induced cyclic myoclonus (P3.013). Neurology, 84 (14 Supplement), P3.013.Google Scholar

The New Psychoactive Substances Review Expert Panel (2014). New Psychoactive Substances: Report of the Expert Panel. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/368583/NPSexpertReviewPanelReport.pdf [Accessed: June 06, 2018]Google Scholar

Thompson, I., Williams, G., Caldwell, B., et al. (2010). Randomised double-blind, placebo-controlled trial of the effects of the 'party pills' BZP/TFMPP alone and in combination with alcohol. Journal of Psychopharmacology, 24(9), 1299–1308.Google Scholar

Tittarelli, R., Mannocchi, G., Pantano, F. & Romolo, F. S. (2015). Recreational use, analysis and toxicity of tryptamines. Current Neuropharmacology, 13(1), 26–46.Google Scholar

Toennes, S. W., Geraths, A., Pogoda, W., et al. (2017). Pharmacokinetic properties of the synthetic cannabinoid JWH-018 and of its metabolites in serum after inhalation. Journal of Pharmaceutical and Biomedical Analysis, 140, 215–222.Google Scholar

Tracy,  D. K., Wood,  D. M. & Baumeister,  D. (2017). Novel psychoactive substances: Identifying and managing acute and chronic harmful use. BMJ, 356. doi: 10.1136/bmj.i6814.Google Scholar

Trecki, J., Gerona, R. R. & Schwartz, M.D. (2015). Perspective: synthetic cannabinoid–related illnesses and deaths. The New England Journal of Medicine, 373(2), 103–107.Google Scholar

Turner, C. F., Ku, L., Rogers, S. M., et al. (1998). Adolescent sexual behavior, drug use, and violence. Science, 280(5365), 867–873.Google Scholar

United Nation Office on Drugs and Crime (UNODC) (2015). Special Segment, Legal responses to NPS: multiple approaches to a multi-faceted problem. Global Smart Update, Vol 14. Available at: www.unodc.org/documents/scientific/Global_SMART_Update_14-web.pdf [Accessed: June 06, 2018]Google Scholar

Ukaigwe, A., Karmacharya, P. & Donato, A. (2014). A gut gone to pot: A case of cannabinoid hyperemesis syndrome due to K2, a synthetic cannabinoid. Case Reports in Emergency Medicine, 167098. http://doi.org/10.1155/2014/167098Google Scholar

Ustundag, M. F., Ozhan Ibis, E., Yucel, A. & Ozcan, H. (2015). Synthetic cannabis-induced mania. Case Reports in Psychiatry. doi: 10.1155/2015/310930.Google Scholar

Valente, M. J., Guedes de Pinho, P., de Lourdes Bastos, M., Carvalho, F. & Carvalho, M. (2014). Khat and synthetic cathinones: A review. Archives of Toxicology, 88(1), 15–45.Google Scholar

Van Amsterdam, J., Brunt, T. & van den Brink, W. (2015). The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. Journal of Psychopharmacology, 29(3), 254–263.Google Scholar

Van Hout, M. C. (2014). An internet study of user's experiences of the synthetic cathinone 4-methylethcathinone (4-MEC). Journal of Psychoactive Drugs, 46(4), 273–286.Google Scholar

Van Hout, M. C. & Brennan, R. (2012). Curiosity killed M-Cat: A post-legislative study on mephedrone use in Ireland. Drugs: Education Prevention and Policy, 19(2), 156–162.Google Scholar

Vento, A. E., Martinotti, G., Cinosi, E., et al. (2014). Substance use in the club scene of Rome: A pilot study. BioMed Research International, 2014, 617546. http://doi.org/10.1155/2014/617546Google Scholar

Vidourek, R. A., King, K. A. & Burbage, M.L. (2013). Reasons for synthetic THC use among college students. Journal of Drug Education, 43(4), 353–363.Google Scholar

Vorce, S. P., Knittel, J. L., Holler, J. M., et al. (2014). A fatality involving AH-7921. Journal of Analytical Toxicology, 38(4), 226–230.Google Scholar

Vreeker, A., van der Burg, B. G., van Laar, M. & Brunt, T.M. (2017). Characterizing users of new psychoactive substances using psychometric scales for risk-related behavior. Addictive Behaviors, 70, 72–78.Google Scholar

Warrick, B. J., Wilson, J., Hedge, M., et al. (2012). Lethal serotonin syndrome after methylone and butylone ingestion. Journal of Medical Toxicology, 8(1), 65–68.Google Scholar

Weinstein, A. M., Rosca, P., Fattore, L. & London, E. D. (2017). Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Frontiers in Psychiatry, 8, 156. http://doi.org/10.3389/fpsyt.2017.00156Google Scholar

Westin, A. A., Frost, J., Brede, W. R., et al. (2016). Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. Journal of Analytical Toxicology, 40(1), 86–87.Google Scholar

White, J., Hawkins, J., Madden, K., et al. (2017). Adapting the ASSIST model of informal peer-led intervention delivery to the Talk to FRANK drug prevention programme in UK secondary schools (ASSIST + FRANK): intervention development, refinement and a pilot cluster randomised controlled trial. Public Health Research, No. 5.7. Southampton (UK): NIHR Journals Library.Google Scholar

Wiley, J. L., Marusich, J. A., Huffman, J. W., Balster, R. L. & Thomas, B. F. (2011). Hijacking of basic research: The case of synthetic cannabinoids. Methods Report (RTI Press), 2011, 17971.Google Scholar

Wilkins, C., Sweetsur, P. & Girling, M. (2008). Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand. Drug and Alcohol Review, 27(6), 633–639.Google Scholar

Wilson, J. M., McGeorge, F., Smolinske, S. & Meatherall, R. (2005). A foxy intoxication. Forensic Science International, 148(1), 31–36.Google Scholar

Winstock, A. R. & Barratt, M. J. (2013). Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug and Alcohol Depend, 131(1–2), 106–111.Google Scholar

Winstock, A. R. & Barratt, M. (2016). Dark-net markets: the good, the bad and ugly? Available at: www.globaldrugsurvey.com/gds2017-launch/dark-net-markets-the-good-the-bad-and-ugly/ [Accessed: December 20, 2017]Google Scholar

Winstock, A., Barratt, M., Ferris, J. & Maier, L. (2017). Global Drug Survey 2017 – Global Overview and Highlights. Available at: www.globaldrugsurvey.com/wp-content/themes/globaldrugsurvey/results/GDS2017_key-findings-report_final.pdf [Accessed: October 17, 2017]Google Scholar

Winstock, A. R., Marsden, J. & Mitcheson, L. (2010). What should be done about mephedrone? BMJ, 340, c1605. doi: 10.1136/bmj.c1605.Google Scholar

Winstock, A. R., Mitcheson, L. R., Deluca, P., et al. (2011). Mephedrone, new kid for the chop? Addiction, 106(1), 154–161.Google Scholar

Wood, D. M., Ceronie, B. & Dargan, P. I. (2016). Healthcare professionals are less confident in managing acute toxicity related to the use of new psychoactive substances (NPS) compared with classical recreational drugs. QJM: An International Journal of Medicine, 109(8), 527–529.Google Scholar

Wood, D. M., Davies, S., Greene, S. L., et al. (2010). Case series of individuals with analytically confirmed acute mephedrone toxicity. Clinical Toxicology (Philadelphia, Pa), 48(9), 924–927.Google Scholar

Wood, D. M., Heyerdahl, F., Yates, C. B., et al. (2014). The European Drug Emergencies Network (Euro-DEN). Clinical Toxicology (Philadelphia, Pa.), 52(4), 239–241.Google Scholar

Wood, D. M., Measham, F. & Dargan, P. I. (2012). ‘Our favourite drug’: prevalence of use and preference for mephedrone in the London night-time economy 1 year after control. Journal of Substance Use, 17(2), 91–97.Google Scholar

Wyman, J. F., Lavins, E. S., Engelhart, D., et al. (2013). Postmortem tissue distribution of MDPV following lethal intoxication by “bath salts”. Journal of Analytical Toxicology, 37(3), 182–185.Google Scholar

Yin, S. & Ho, M. (2012). Monitoring a toxicological outbreak using Internet search query data. Clinical Toxicology (Philadelphia, Pa.), 50(9), 818–822.Google Scholar

Zawilska, J. B. (2017). An expanding world of novel psychoactive substances: Opioids. Frontiers in Psychiatry, 8, 110. http://doi.org/10.3389/fpsyt.2017.00110Google Scholar

Zawilska, J. B. & Wojcieszak, J. (2017). α-Pyrrolidinophenones: A new wave of designer cathinones. Forensic Toxicology, 35(2), 201–216.Google Scholar

Zheluk, A., Quinn, C. &, Meylakhs, P. (2014). Internet search and krokodil in the Russian Federation: An infoveillance study. Journal of Medical Internet Research, 16(9), e212. doi: 10.2196/jmir.3203Google Scholar

Alexander, B. H., Checkoway, H., Nagahama, S. I. & Domino, K. B. (2000). Cause-specific mortality risks of anesthesiologists. Anesthesiology, 93(4), 922–930.Google Scholar

American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Arlington, VA: American Psychiatric Publishing.Google Scholar

American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (5th edition). Arlington, VA: American Psychiatric Publishing.Google Scholar

Angres, D. H. (2010). The temperament and character inventory in addiction treatment. Focus, 8(2), 187–198. doi:10.1176/foc.8.2.foc187Google Scholar

Angres, D. H. & Nielsen, A. K. (2007). The role of the TCI-R (Temperament Character Inventory) in individualized treatment plannning in a population of addicted professionals. Journal of Addictive Diseases, 26 (Supplement 1), 51–64. doi:10.1300/J069v26S01_06Google Scholar